Calcifediol supplementation in adults on hemodialysis: a randomized controlled trial

Area of Science:

• Nephrology
• Endocrinology
• Clinical Trials

Background:

• Vitamin D deficiency is linked to higher mortality in chronic kidney disease patients.
• The impact of vitamin D supplementation on cardiovascular outcomes and mortality in this group remains unclear.
• This study investigated calcifediol's effectiveness in reducing mortality among hemodialysis patients with vitamin D insufficiency.

Purpose of the Study:

• To assess the effectiveness of calcifediol in reducing mortality in patients with vitamin D insufficiency undergoing hemodialysis.
• To evaluate the impact of calcifediol supplementation on cardiovascular outcomes.
• To compare calcifediol therapy against standard care in a hemodialysis population.

Main Methods:

• A phase III, multicenter, randomized, open-label trial.
• 284 adults with vitamin D insufficiency undergoing hemodialysis were included.
• Participants received oral calcifediol or standard care for 24 months.

Main Results:

• Mortality occurred in 34 participants in the calcifediol group and 31 in the control group (HR 1.03; 95% CI 0.63-1.67).
• Calcifediol showed no significant effect on cardiovascular death, non-cardiovascular death, myocardial infarction, or stroke.
• Incidence of hypercalcemia and hyperphosphatemia was similar between groups, with no parathyroidectomies performed.

Conclusions:

• Calcifediol supplementation for 24 months had inconclusive effects on mortality in hemodialysis patients with vitamin D insufficiency.
• No significant impact on cardiovascular outcomes was detected with calcifediol treatment.
• Further research may be needed to clarify the role of vitamin D supplementation in this patient population.